logo

Regenxbio Inc (RGNX)



Trade RGNX now with
  Date
  Headline
11/26/2018 8:39:32 AM Rocket Pharma, REGENXBIO Unveil License Agreement For Treatment Of Danon Disease Using NAV AAV9 Vector
11/26/2018 8:39:25 AM REGENXBIO, Rocket Announce New License Agreement For Treatment Of Danon Disease Using NAV AAV9 Vector
10/22/2018 7:18:12 AM REGENXBIO Announces Worldwide License With Ultragenyx For CDKL5 Deficiency Disorder Using NAV Vectors
10/4/2018 7:03:55 AM Regenxbio Unveils Completion Of Dosing Of Fourth Cohort In Phase I Trial Of RGX-314 Gene Therapy For Wet AMD
8/8/2018 7:38:42 AM REGENXBIO Q2 Revenues $40.0 Mln Vs. $6.6 Mln Prior Year
5/29/2018 4:11:14 PM REGENXBIO Appoints Alexandra Glucksmann To Board Of Directors
5/2/2018 7:08:59 AM REGENXBIO Receives FDA Fast Track Designation For RGX-121 Gene Therapy For Mucopolysaccharidosis Type II
1/8/2018 8:36:52 AM AveXis Acquires Exclusive Rights To Entire NAV Technology Platform For Development Of Treatments For SMA
1/8/2018 8:26:32 AM AveXis Acquires Exclusive Rights To Entire NAV Technology Platform For The Development Of Treatments For SMA